44 results on '"García-Carro, Clara"'
Search Results
2. Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology
- Author
-
Alonso, Fabiola, Martín de Francisco, Ángel L.M., Auñón, Pilar, García-Carro, Clara, García, Patricia, Gutiérrez, Eduardo, Mcía, Manuel, Quintana, Luis F., Quiroga, Borja, Soler, María José, and Torregrosa, Isidro
- Published
- 2023
- Full Text
- View/download PDF
3. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
- Author
-
Alarmartine, Eric, Barratt, Jonathan, Chae, Dong Wan, Del Vecchio, Lucia, Floege, Jurgen, Hwang, Shang-Jyh, Jelakovic, Bojan, Maes, Bart, Malecki, Robert, Miglinas, Marius, Nolasco, Fernando Eduardo Barbosa, Praga, Manual, Rabindranath, Kannaiyan, Rosenberg, Mai, Rovin, Brad, Tang, Sydney Chi Wai, Tesar, Vladmir, Wong, Muh Geot, Bose, Bhadran, Gangadharan, Muralikrishna, McDonald, Stephen, Peh, Chen, Jahan, Sadia, Yeap, Chii, Clayton, Philip, Irish, Georgina, Thyagarajan, Nikhil, Hollett, Peter, Krishnasamy, Rathika, Carroll, Robert, Jesudason, Shilpanjali, Crail, Susan, Coates, Toby, Waugh, Jane, Noble, Euan, Mahadevan, Kumaradevan, Campbell, Victoria, Salehi, Tania, Lim, Wai, Boudville, Neil, Chakera, Aron, Chan, Doris, Krishnan, Anoushka, Eqbal, Yusuf, Gillies, Alastair, Vilayur, Eswari, Maung Myint, Thida Maung, Gray, Nicholas, Cheetham, Melissa, Pollock, Carol, Cooper, Bruce, Mather, Amanda, Roxburgh, Sarah, Shen, Yvonne, Stangenberg, Stefanie, Siriwardana, Amanda, O'Lone, Emma, Wan, Susan, Neuen, Brendon, Tsun Kit Ha, Jeffrey, Kim, Dana, Heath, Lauren, Jain, Arunima, Phua, Elaine, Li, Yan, Gallagher, Martin, Jardine, Meg, Ritchie, Angus, Razavian, Mona, Foote, Celine, Wyndham, Roger, Sen, Shaundeep, Endre, Zoltan, Erlich, Jonathan, Fernando, Mangalee, Yong, Kenneth, Luxton, Grant, Kotwal, Sradha, Roger, Simon, Wijeratne, Vidu, Packham, David, Fraser, Ian, Vandewiele, Bert, Laute, Margo, Lemahieu, Wim, Jamar, Sofie, Ombelet, Sara, Meeus, Gert, Decupere, Marc, Schockaert, Olivier, Doubel, Peter, Viaene, Liesbeth, Radermacher, Luc, Masset, Catherine, Moonen, Martial, Firre, Eric, Milicevic, Martina, Warling, Xavier, Vanacker, An, Malfait, Thomas, Durlen, Ivan, Horvatic, Ivica, Savuk, Ana, Gellineo, Lana, Karanovic, Sandra, Dika, Zivka, Plavljanic, Djuro, Mikacic, Ivana, Trajbar Kentric, Dubravka, Barisic, Dunja, Stankovic, Marija, Majstorovic Barac, Karolina, Kruljac, Ivan, Pavlovic, Drasko, Drinkovic, Martin, Prkacin, Ingrid, Barbic, Jerko, Sitas, Zvonimir, Vujcic, Dunja, Rychlik, Ivan, Benesova, Anna, Drinovska, Klara, Kratka, Karolina, Maixnerova, Dita, Ilmoja, Madis, Unt, Kristin, Lilienthal, Kadri, Auerbach, Asta, Leis, Liisi, Piel, Julia, Adoberg, Annika, Kolvald, Kulli, Veermae, Kristi, Telling, Kadri, Seppet, Elviira, Uhlinova, Jana, Zaoui, Philippe, Carron, Pierre-Louis, Masson, Ingrid, Dinic, Miriana, Thibaudin, Damien, Broyet, Christian, Maillard, Nicolas, Mohey, Hesham, Mariat, Christophe, Claisse, Guillaume, Alamartine, Eric, Dussol, Bertrand, Burtey, Stephane, Chiche-Jourde, Noemie, Serre, Jean-Emmanuel, Jeantet, Guillaume, Chenine, Leila, Blanchard, Anne, Roueff, Stephane, Thervet, Eric, Fouassier, David, Buffet, Alexandre, Livrozet, Marine, Gaisset, Roxane, Karras, Alexandre, Heng, Anne-Elisabeth, Garrouste, Cyril, Philipponnet, Carole, Nicolo, Clementine, Atenza, Alba, Lanaret, Camille, Greze, Clarisse, Mayet, Valentin, Dumond, Clement, Delmas, Yahsou, Combe, Christian, Rigothier, Claire, Burguet, Laure, Labat, Aurore, Mucha, Simon, de Précigout, Valérie, Weinreich, Thomas, Reichel, Helmut, Draganova, Diliana, Wolf, Lothar, Hohenstein, Bernd, Heinrichs, Sven, Kulka, Simone, Sat, Sebahat, Weiland, Lea, Krueger, Thilo, Wolf, Gunter, Kettner, Christiane, Schlosser, Mandy, Herfurth, Johann Konstantin, Koch, Annegret, Busch, Martin, Werth, Stephan Christian, Nitschke, Martin, Cakiroglu, Figen, Sarnow, Franziska, Schulz, Lisa, Weiner, Stefan, Wirtz, Nikolaus, Koester, Eric, Moeller, Marcus, Stamellou, Eleni, Sanden, Silja, Schmidt-Guertler, Hans, Bernhardt, Wanja, Patecki, Margret, Schlieper, Georg, Schulte, Kevin, Girardet, Annette, Kunzendorf, Ulrich, Kwan, Lorraine Pui Yuen, Mok, Maggie Ming Yee, Chan, Gary Chi Wang, Ma, Mingyao, Lie, Davina Ngoi Wah, Chan, Anthony Ting Pong, Szeto, Cheuk Chun, Ng, Kit Chung Jack, Cheung, Siu Fai, Yue, Tak Tai Andrew, Fung, Ka Shun Samuel, Tang, Hon, Yim, Ka Fai, Law, Wai Ping, Wong, Yick Hei, Lam, Chi Kwan Darwin, Wong, Sze Ho Sunny, Marcantoni, Carmelita, Aliotta, Roberta, Deodato, Francesca, Patella, Gemma, Comi, Nicolino, Vita, Caterina, Carullo, Nazareno, Bolignano, Davide, Musolino, Michela, Trillini, Matias, Perico, Norberto, Remuzzi, Giuseppe, Daina, Erica, Biancone, Luigi, Colla, Loredana, Burdese, Manuel, Cogno, Chiara, Boaglio, Elena, Abbasciano, Isabella, Zizzi, Carlotta Federica, Randone, Paolo, Napodano, Pietro, Ricchiuto, Anna, Cassia, Matthias, Accarino, Simone, Cozzolino, Mario, Baccaro, Rocco, Costanzi, Stefano, Di Maio, Federica, Arena, Maria, Urciuolo, Federica, Vigano, Sara, Cavalli, Andrea, Limardo, Monica, Bordoli, Monica, Ponti, Serena, Longhi, Selena, Solazzo, Andrea, Giaroni, Francesco, Donati, Gabriele, Torreggiani, Massimo, Catucci, Davide, Colucci, Marco, Esposito, Vittoria, Esposito, Ciro, Gesualdo, Loreto, Capaccio, Flavia, Diletta Stea, Emma, Sivo, Carmen, Annese, Francesca, Papadia, Federica, Messa, Piergiorgio, Belingheri, Mirco, Passerini, Patrizia, Malvica, Silvia, Vickiene, Alvita, Zakauskiene, Urte, Asakiene, Egle, Bumblyte', Inga Arune, Stankuviene, Asta, Santockiene, Lina, Hayat, Ashik, Williams, Allister, Sizeland, Peter, Tan, Eddie, Waters, Gerald, Chan, Lai Wan, Henderson, Andrew, Turnbull, Angus, McNally, Andrew, Reynolds, Annie, Pilmore, Helen, Dittmer, Ian, Manley, Paul, Stallworthy, Elizabeth, Goh, Tze, Semple, David, Collins, Michael, Curry, Elizabeth, Ahmed, Jafar, Nguyen, Thu, Winiarska, Agata, Zbrzezniak, Justyna, Stompor, Tomasz, Krajewska, Magdalena, Augustyniak-Bartosik, Hanna, Zielinska, Dorota, Jander, Anna, Stanczyk, Malgorzata, Tkaczyk, Marcin, Miarka, Przemyslaw, Aksamit, Dariusz, Jaskowski, Piotr, Sulowicz, Wladyslaw, Cieniawski, Dominik, Gontarek-Kacprzak, Julita, Felicjanczuk, Elzbieta, Kwella, Norbert, Kwella, Bogna, Satora, Ewa, Fernandes, João Carlos, Gomes, Ana Marta, Reis, Marina, Lopes, Daniela, Almeida, Catarina, Sá, Helena, Figueiredo, Ana Carolina, Pardinhas, Clara, Almeida, Edgar, Raimundo, Mario, Cortesão Costa, Ana, Falcao Goncalves, Luis Pedro, Fernandes, Sara, Silva, Sónia, Teixeira, Catarina, Fernandes, Adriana, Nolasco, Fernando, Alves, Patricia, Gois, Mario, Fonseca, Nuno, Messias, Ana, Menezes, Maria, Cardoso, Filipa, Sousa, Helena, Marques, Joana, Barata, Rui, Lopes, Jose Antonio, Jorge, Sofia, Gameiro, Joana, de Almeida Agapito Fonseca, Jose Nuno, Goncalves, Sara, Farinha, Ana, Valerio Santos, Patricia, Natario, Ana, de Jesus Barreto, Jose Carlos, Abrantes, Catarina, Quadrado Soares, Elsa Sofia, Soares Felgueiras, Joana de Sousa, Cunha, Liliana, Parreira, Lucia, Furtado, Teresa, Vaz, Alvaro, Oh, Kook-Hwan, Lee, Hajeong, Joong Kim, Se, Jeong, Jong Cheol, Hoon Kim, Yeong, Kim, Yunmi, Park, Hyeong Cheon, Choi, Hoon Young, Wook Kim, Hyung, Lee, Moon Hyoung, Yoon, Songuk, Lee, Kyu-Beck, Hyun, YoungYoul, Yoo, Tae-Hyun, Han, Seung Hyeok, Park, Jung Tak, Kim, Sunggyun, Song, Young Rim, Kim, Jwa-Kyung, Lee, Hyung-seok, Joo, Narae, Lee, JungEun, Ryoun Jang, Hye, Jeon, Junseok, Chung, Wookyung, Lee, HyunHee, Chang, Jae Hyun, Chun, Ka Yeong, Jung, Ji Yong, Ro, Han, Kim, Aejin, Jo, Sang-Kyung, Yang, Jihyun, Kim, Myung-Gyu, Oh, SeWon, Martinez Villanueva, Caridad, Gimeno, Ana Vilar, Andres Useche Bonilla, Gustavo, Tamarit, Esther, Galan Serrano, Antonio, Verde Moreno, Eduardo, Fernandez, Jose Luño, Goicoechea Diezhandino, Maria Angeles, Verdalles Guzman, Ursula, de Jose, Ana Perez, Ortiz Arduan, Alberto, Pérez Gómez, María Vanessa, Martín Cleary, Catalina, Prado, Raul Fernandez, Goma, Elena, Ballarin, Jose, Encarnacion, Montserrat Diaz, Da Silva Santos, Iara, Marco Rusinol, Helena, Furlano, Monica, Arias, Carlos, Barrios, Clara, Garcia, Eva Rodriguez, Sierra Ochoa, Adriana, Vizcaino Castillo, Belen, Pantoja Perez, Jonay, Gonzalez Moya, Mercedes, Sargsyan, Mari, Calatayud Aristoy, Emma, Bernabeu, Ana Avila, Perez Lluna, Leticia, Malek Marin, Tamara, Antonia Munar Vila, Maria, Bobadilla Rico, Ivon Maritza, Allende Burgos, Natalia, Gutierrez Martinez, Eduardo, Gutierrez Solis, Elena, Sevillano, Angel, Merida Herrero, Evangelina, Miquel Blasco Pelicano, Josep, Rodas Marin, Lida Maria, Quintana, Luis F, Antonieta Azancot Rivero, Maria, Ramos Terrades, Natalia, Garcia Carro, Clara, Agraz Pamplona, Irene, Salgueira Lazo, Mercedes, de la Prada Alvarez, Francisco, Alonso Garcia, Fabiola, Adrian Aguilera Morales, Wenceslao, Virxinia Pol Heres, Salia, Forcen, Angel, Parra Moncasi, Eduardo, Medrano Villarroya, Cristina, Soria Villen, Alejandro, Gracia Garcia, Olga, Velo Plaza, Mercedes, Sánchez de la Nieta, Maria Dolores, Calvo Arevalo, Marta, Moreno, Antolina, Cigarran Guldris, Secundino, de Vicente, Manuel Pereira, Munar Vila, Maria Antonia, Hsu, Bang-Gee, Wang, Chih-Hsien, Chen, Cheng-Hsu, Yu, Tung-Min, Wu, Ming-Ju, Tsai, Shang-Feng, Hsu, Chia-Tien, Chiu, Hsien-Fu, Chou, Kang-Ju, Fang, Hua-Chang, Lee, Po-Tsang, Chen, Hsin-Yu, Chen, Chien-Liang, Huang, Chien-Wei, Ou, Shih-Hsiang, Ho, Tzung-Yo, Hsu, Chih-Yang, Chang, Ming-Shan, Chiu, Yen-Ling, Peng, Yu-Sen, Shu, Kai-Hsiang, Pan, Szu-Yu, Hsu, Shih-Ping, Yang, Ju-Yeh, Pai, Mei-Fen, Tseng, Po-Yu, Wu, Hon-Yen, Tsai, Wan-Chuan, Tung, Kuei-Ting, Chen, Hung-Yuan, Chen, Hung-Chun, Kuo, Mei-Chuan, Hwang, Daw-Yang, Chiu, Yi-Wen, Hung, Chi-Chih, Kuo, Hung-Tien, Tsai, Jer-Chia, McCafferty, Kieran, Forbes, Suzanne, Dasgupta, Indranil, Thomas, Mark, Mahdi, Amar, Ajayi, Bamidele, Chowdhury, Paramit, Kasimatis, Theodoros, Moutzouris, Dimitrios, Dudreuilh, Caroline, Pruthi, Rishi, Mansfield, Nick, Doctor, Gabriel, Shah, Sapna, Kon, Sui, Smith, Priscilla, Hamilton, Patrick, Kanigicherla, Durga, Ibrahim Ragy, Omar Sherin, Alchi, Bassam, Flossmann, Oliver, Ghalli, Farid, Lawman, Sarah, Sinha, Smeeta, Chrysochou, Constantina, Chukwu, Chukwuma, Maire De Bhailis, Aine, Al Chalabi, Saif, Hudson, Amy, Gopu, Arun, Wickens, Olivia, Storrar, Joshua, Wahba, Mona, Lorde, Nathan, Rony, Mohammad, Griffin, Sian, Latif, Farah, Ali, Mohammad, DaSilva, Louise, Ayling-Smith, Jonathan, Mahdi, Eamon, Willcocks, Lisa, Jones, Rachel, Cheung, Chee Kay, Selvaskandan, Haresh, Pugh, Dan, Sayer, Matthew, Dhaun, Neeraj, Chapman, Fiona, Mark, Patrick, Geddes, Colin, McQuarrie, Emily, Patel, Rajan, Solomon, Laurence, Ponnusamy, Arvind, Morris, Adam, Okoh, Pedro, Floyd, Lauren, Dhaygude, Ajay, Leung, Janson, Goldsmith, Christopher, Pandya, Bhavna, Tez, Didem, Mikhail, Ashraf, Brown, Karen, Bucknall, Thomas, Lambie, Mark, Comunale, Roderick, Brandon, Donald, Martinez, Stacy, Hall, Amanda, Henderson, Amy, Fearday, Aaron, Douthit, Nicole, Snow, Brian, Silva, Arnold, Sly, Cathylee, Keller, Christopher, Davidson, Robert, Meng, Jerry, Haws, Robert, Kattamanchi, Siddhartha, Mojarrab, Javad, Pillai, Unnikrishnan, Lafayette, Richard, O'Shaughnessy, Michelle, Kamal, Fahameedah, Mehta, Kshama, Baker, Bruce, Ruiz, Mario, Jyothinagaram, Praveena, Peri, Usha, Paxton, William, Tumlin, James, McGreal, Kerri, McCarthy, Ellen, Kimber, Cassandra, Gautam, Archana, Khalil, Kassem, Nguyen, Viet, Minasian, Raffi, Arfaania, Dariush, Daneshvari, Sam, Zakari, Michel, Patrikyan, Artashes, Afsari, Rouzbeh, Ayvazyan, Christine, Fakih, Faisal, Lagatta, Mark, Rodriguez, Alfred, Avella, Jorge Enrique Monroy, Patak, Ramachandra, Kadakia, Jigar, Radhakrishnan, Jai, Appel, Gerald, Ahn, Wooin, Nelson, Bradley, Medina, Allyson, Ahmad, Syeda, Peleg, Yonatan, Clement, Nisha, Chiu, Ian, Hendren, Elizabeth, Bomback, Andrew, Canetta, Pietro, Spinowitz, Bruce, Charytan, Chaim, Parikh, Nishita, Kuo, Sheng, Raichoudhury, Ritesh, Dobre, Mirela, Negrea, Lavinia, Padiyar, Aparna, Jittirat, Arksarapuk, Pradhan, Nishigandha, Dhelaria, Ranjit, Balamuthusamy, Saravanan, Madhrira, Machaiah, Powell, Thomas, Lifland, Howard, Bailey, Asha, Ford Sightler, Sarah Ashley, Suthar, Meera Patel, Green, Heather, Parikh, Samir, Ayoub, Isabelle, Almaani, Salem, Contreras, Gabriel, Fornoni, Alessia, Drexler, Yelena, Geara, Abdallah, Sheridan, Brittany, Coppock, Gaia, Hogan, Jonathan, Gonzalez, Carlos, Bhadra, Shamik, Chowdhury, Pradip, Kyaw, Kay, Tan, May, Raakesh, Lathika, Mendoza, Elder, Viramontes, Veronica, Chaudhry, Asghar, Carbonell, Juan, Gadh, Rajdeep, Fernandez, Victor, Kassem, Mohamad, Jacob, Radu, Wilder, Karen, Newsome, Britt, Klamm, Kathryn, Suyumova, Irina, Kooienga, Laura Ann, Janko, Catherine, Rizk, Dana, Julian, Bruce, Caster, Dawn, Perez, Erika, Garg, Gunjan, Gowda, Nayan, Udani, Suneel, Mandayam, Sreedhar, Workeneh, Biruh, Assefi, Ali, Greco, Barbara, Germain, Michael, Patel, Jusmin, Quinn, Sarah, Sullivan, James, Glaze, Jeffrey, Madonia, Phillip, McMahon, Kellyn, Giles, Harold, Adler, Sharon, Dai, Tiane, Heerspink, Hiddo J L, Alpers, Charles E, Bieler, Stewart, Diva, Ulysses, Inrig, Jula, Komers, Radko, Mercer, Alex, Noronha, Irene L, Rheault, Michelle N, Rote, William, Trachtman, Howard, Trimarchi, Hernán, and Perkovic, Vlado
- Published
- 2023
- Full Text
- View/download PDF
4. Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis
- Author
-
Rojas-Rivera, Jorge E., García-Carro, Clara, Ávila, Ana I., Espino, Mar, Espinosa, Mario, Fernández-Juárez, Gema, Fulladosa, Xavier, Goicoechea, Marian, Macía, Manuel, Morales, Enrique, Porras, Luis F. Quintana, and Praga, Manuel
- Published
- 2023
- Full Text
- View/download PDF
5. Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring
- Author
-
Waldman, Meryl, Soler, Maria Jose, García-Carro, Clara, Lightstone, Liz, Turner-Stokes, Tabitha, Griffith, Megan, Torras, Joan, Valenzuela, Laura Martinez, Bestard, Oriol, Geddes, Colin, Flossmann, Oliver, Budge, Kelly L., Cantarelli, Chiara, Fiaccadori, Enrico, Delsante, Marco, Morales, Enrique, Gutierrez, Eduardo, Niño-Cruz, Jose A., Martinez-Rueda, Armando J., Comai, Giorgia, Bini, Claudia, La Manna, Gaetano, Slon, Maria F., Manrique, Joaquin, Agraz, Irene, Sinaii, Ninet, and Cravedi, Paolo
- Published
- 2021
- Full Text
- View/download PDF
6. Utility of transjugular renal biopsy as an alternative to percutaneous biopsy
- Author
-
Bolufer, Mónica, García-Carro, Clara, Agraz, Irene, Díez Miranda, Iratxe, Jaramillo, Juliana, Arredondo, Karla, Bury, Roxana, Ramos, Natalia, Azancot, Maria A., Gabaldón, Alejandra, Pérez Lafuente, Mercedes, Espinel, Eugenia, Segarra, Alfons, Serón, Daniel, and Soler, María José
- Published
- 2020
- Full Text
- View/download PDF
7. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies.
- Author
-
León-Román, Juan, Iacoboni, Gloria, Bermejo, Sheila, Carpio, Cecilia, Bolufer, Mónica, García-Carro, Clara, Sánchez-Salinas, Mario, Alonso-Martínez, Carla, Bestard, Oriol, Barba, Pere, and Soler, María José
- Subjects
CHIMERIC antigen receptors ,ACUTE kidney failure ,HEMATOLOGIC malignancies ,CYTOKINE release syndrome ,T cells ,HEART failure ,IMMUNE reconstitution inflammatory syndrome - Abstract
Background Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes after AKI in patients who received CAR T-cell therapy. Methods Medical records of 115 adult patients with R/R hematological malignancies treated with CD19-targeted CAR T-cells at Vall d'Hebron University Hospital between July 2018 and May 2021. Baseline demographic data including age, gender, ethnicity, body mass index (BMI), and co-morbidities, as well as the type of hematological neoplasia and prior lines of therapy were collected. Laboratory parameters including serum creatinine and whole blood hemoglobin were retrospectively reviewed and values were gathered for days +1, +7, +14, +21, and +28 post-infusion. Results A total of 24/115 (21%) patients developed AKI related to CAR T-cell therapy; 6/24 with AKI over chronic kidney disease (CKD). Two patients had AKI in the context of lymphodepleting (LD) chemotherapy and the other 22 after CAR T-cell infusion, starting at day+1 in 3 patients, day+7 in 13 patients, day +14 in 1 patient, day+21 in 2 patients, and day+28 in 3 patients. Renal function was recovered in 19/24 (79%) patients within the first month after infusion. Male gender, CKD, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with AKI. Male gender, CKD, ICANS grade ≥3 and CRS grade ≥2 were identified as independent risk factors for AKI on multivariable analysis. In terms of the most frequent CAR T-cell related complications, CRS was observed in 95 (82%) patients and ICANS in 33 (29%) patients. Steroids were required in 34 (30%) patients and tocilizumab in 37 (32%) patients. Six (5%) patients were admitted to the intensive care unit (1 for septic shock, 4 for CRS grade ≥2 associated to ICANS grade ≥2, and 1 for CRS grade ≥3). A total of 5 (4.4%) patients died in the first 30 days after CAR T-cell infusion for reasons other than disease progression, including 4 cases of infectious complications and 1 of heart failure. Conclusion Our results suggest that AKI is a frequent but mild adverse event, with fast recovery in most patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Genetic testing in focal segmental glomerulosclerosis: in whom and when?
- Author
-
Tato, Ana María, Carrera, Noa, García-Murias, Maria, Shabaka, Amir, Ávila, Ana, Mora, María Teresa Mora, Rabasco, Cristina, Soto, Karina, Alvarez, Francisco Jose de la Prada, Fernández-Lorente, Loreto, Rodríguez-Moreno, Antolina, Huerta, Ana, Mon, Carmen, García-Carro, Clara, Cabrera, Fayna González, Navarro, Juan Antonio Martín, Romera, Ana, Gutiérrez, Eduardo, Villacorta, Javier, and Lorenzo, Alberto de
- Subjects
FOCAL segmental glomerulosclerosis ,GENETIC testing ,GLOMERULAR filtration rate ,BODY mass index ,SERUM albumin ,GENETIC variation ,PEDIATRIC nephrology - Abstract
Background Genetic causes are increasingly recognized in patients with focal segmental glomerulosclerosis (FSGS), but it remains unclear which patients should undergo genetic study. Our objective was to determine the frequency and distribution of genetic variants in steroid-resistant nephrotic syndrome FSGS (SRNS-FSGS) and in FSGS of undetermined cause (FSGS-UC). Methods We performed targeted exome sequencing of 84 genes associated with glomerulopathy in patients with adult-onset SRNS-FSGS or FSGS-UC after ruling out secondary causes. Results Seventy-six patients met the study criteria; 24 presented with SRNS-FSGS and 52 with FSGS-UC. We detected FSGS-related disease-causing variants in 27/76 patients (35.5%). There were no differences between genetic and non-genetic causes in age, proteinuria, glomerular filtration rate, serum albumin, body mass index, hypertension, diabetes or family history. Hematuria was more prevalent among patients with genetic causes. We found 19 pathogenic variants in COL4A3–5 genes in 16 (29.3%) patients. NPHS2 mutations were identified in 6 (16.2%) patients. The remaining cases had variants affecting INF2, OCRL, ACTN4 genes or APOL1 high-risk alleles. FSGS-related genetic variants were more common in SRNS-FSGS than in FSGS-UC (41.7% vs 32.7%). Four SRNS-FSGS patients presented with NPHS2 disease-causing variants. COL4A variants were the most prevalent finding in FSGS-UC patients, with 12 patients carrying disease-causing variants in these genes. Conclusions FSGS-related variants were detected in a substantial number of patients with SRNS-FSGS or FSGS-UC, regardless of age of onset of disease or the patient's family history. In our experience, genetic testing should be performed in routine clinical practice for the diagnosis of this group of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. The need for renal biopsy in oncology patients on check-point inhibitors check-point inhibitors: New triggers for extracapillary glomerulonephritis extracapillary glomerulonephritis
- Author
-
Sanchez de la Nieta Garcia, M. Dolores, Juez del Pozo, Almudena, Cortés Toro, José Antonio, Rodríguez Moreno, Antolina, García Carro, Clara, Ruiz Ferreras, Elena, and Sánchez Fructuoso, Ana Isabel
- Published
- 2023
- Full Text
- View/download PDF
10. Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN).
- Author
-
Rojas-Rivera, Jorge E, García-Carro, Clara, Ávila, Ana I, Espino, Mar, Espinosa, Mario, Fernández-Juárez, Gema, Fulladosa, Xavier, Goicoechea, Marian, Macía, Manuel, Morales, Enrique, Quintana, Luis F, and Praga, Manuel
- Subjects
- *
LUPUS nephritis , *DIAGNOSIS , *SYSTEMIC lupus erythematosus , *DISEASE remission , *CLINICAL trials , *KIDNEY glomerulus diseases - Abstract
Lupus nephritis (LN) is the most frequent serious manifestation of patients with systemic lupus erythematosus (SLE). Up to 60% of SLE patients develop LN, which has a significant impact on their quality of life and prognosis. Recent advances have improved the diagnostic approach to LN, and new drugs that block specific pathways and kidney damage progression have been developed. Several randomized and well-powered clinical trials have confirmed the efficacy of these agents in terms of proteinuria remission and preservation of kidney function in the medium and long term, with an acceptable safety profile and good tolerance. The combination of different therapies allows for reduction of the dose and duration of corticosteroids and other potentially toxic therapies and leads to an increase in the number of patients achieving complete remission of the disease. This consensus document carried out by the Spanish Group for the Study of Glomerular Diseases (GLOSEN) provides practical and updated recommendations, based on the best available evidence and clinical expertise of participating nephrologists. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Focal and segmental glomerulosclerosis associated with COVID-19 infection
- Author
-
León Román, Juan, Vergara Arana, Ander, Agraz Pamplona, Irene, García Carro, Clara, Bermejo Garcia, Sheila, Gabaldon Dominguez, Alejandra, Soler Romeo, Maria Jose, Institut Català de la Salut, Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Glomerulosclerosi - Tractament ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Diseases of the genitourinary system. Urology ,Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores] ,Nephrology ,Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Nephritis::Glomerulonephritis::Glomerulosclerosis, Focal Segmental [DISEASES] ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,RC870-923 ,enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::nefritis::glomerulonefritis::glomeruloesclerosis focal [ENFERMEDADES] ,Letter to the Editor ,COVID-19 (Malaltia) - Complicacions ,Other subheadings::Other subheadings::/complications [Other subheadings] - Abstract
Glomeruloesclerosi; COVID-19 Glomerulosclerosis; COVID-19 Glomeruloesclerosis; COVID-19
- Published
- 2021
12. Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity.
- Author
-
García-Carro, Clara, Draibe, Juliana, and Soler, María José
- Published
- 2023
- Full Text
- View/download PDF
13. Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer
- Author
-
Campedel, Luca, Salem, Joe-Elie, Bagnis, Corinne Isnard, Gupta, Shruti, Leaf, David E., Singh, Harkarandeep, Motwani, Shveta S., Murakami, Naoka, Tio, Maria C., Mothi, Suraj S., Selamet, Umut, Weins, Astrid, Loew, Sebastian, Schmidt-Ott, Kai M., Chang, Weiting, Jhaveri, Kenar D., Wanchoo, Rimda, Khanin, Yuriy, Hirsch, Jamie S., Sakhiya, Vipulbhai, Stalbow, Daniel, Wu, Sylvia, Ortiz-Melo, David I., Ostermann, Marlies, Lumlertgul, Nuttha, Seylanova, Nina, Cennamo, Armando, Rigg, Anne, Shaunak, Nisha, Kibbelaar, Zoe A., Benesova, Karolina, Deshpande, Priya, Sise, Meghan E., Reynolds, Kerry L., Seethapathy, Harish S., Lee, Meghan, Strohbhen, Ian A., Mooradian, Meghan J., Hanna, Paul E., Wang, Qiyu, Seethapathy, Rituvanthikaa, Herrmann, Sandra M., Isik, Busra, Glezerman, Ilya G., Cortazar, Frank B., Aggarwal, Vikram, Chandra, Sunandana, Prosek, Jason M., Madhavan, Sethu M., Owen, Dwight H., Husain, Marium, Beckerman, Pazit, Mini, Sharon, Anand, Shuchi, Garcia, Pablo, Kaghazchi, Aydin, Rangarajan, Sunil, Shin, Daniel Sanghoon, Cherry, Grace, Carlos, Christopher A., Hsu, Raymond K., Kisel, Andrey, Rashidi, Arash, Kansal, Sheru K., Albert, Nicole, Carter, Katherine, Donley, Vicki, Young, Tricia, Cigoi, Heather, De Seigneux, Sophie, Koessler, Thibaud, Sprangers, Ben, Wauters, Els, Shah, Chintan V., Eijgelsheim, Mark, Mithani, Zain, Pagan, Javier A., Zuo, Yiqin, Coppock, Gaia, Hogan, Jonathan J., Abudayyeh, Ala, Mamlouk, Omar, Lin, Jamie S., Page, Valda, Kitchlu, Abhijat, Short, Samuel A.P., Renaghan, Amanda D., Gaughan, Elizabeth M., Malik, A. Bilal, Soler, Maria Jose, García-Carro, Clara, Bermejo, Sheila, Felip, Enriqueta, Muñoz-Couselo, Eva, Carreras, Maria Josep, Strohbehn, Ian A., Chang, Wei-Ting, and de Seigneux, Sophie
- Published
- 2022
- Full Text
- View/download PDF
14. WCN24-2513 TRANSIENT ACUTE KIDNEY INJURY AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
- Author
-
Soler Romeo, María José, Iacoboni, Gloria, Bermejo, Sheila, Carpio, Cecilia, Bolufer, Mónica, García-Carro, Clara, Sánchez, Mario, Alonso-Martínez, Carla, Barba, Pere, and Arana, Ander Vergara
- Published
- 2024
- Full Text
- View/download PDF
15. Revisiting the role of acute kidney injury in patients on immune checkpoint inhibitors: a good prognosis renal event with a significant impact on survival.
- Author
-
García-Carro, Clara, Jhaveri, Kenar D, and Sprangers, Ben
- Subjects
- *
IMMUNE checkpoint inhibitors , *ACUTE kidney failure , *DRUG side effects , *IPILIMUMAB , *KIDNEY diseases , *PROGNOSIS - Abstract
In the last decade, immune checkpoint inhibitors (ICI) have become a cornerstone in the treatment of a wide range of malignancies. It is well established that ICI are associated with multiple immune-related adverse events, a spectrum of autoimmune toxicities, that can also affect the kidney. In this issue of Clinical Kidney Journal , Kanbay et al. report the first meta-analysis and systematic review evaluating the impact of ICI-related acute kidney injury (ICI-AKI) on long-term kidney and patient outcomes (including mortality). The authors report a high incidence of ICI-AKI (mostly mild AKI episodes) with high rates of recovery resulting in a good kidney outcomes. However, the occurrence of ICI-AKI has a significant impact on mortality in ICI-treated patients probably related to temporary or definitive cessation of ICI. Additional studies are needed to establish the safety of ICI re-challenging in patients with ICI-AKI, and to determine the optimal treatment strategy for them. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Focal and segmental glomerulosclerosis associated with COVID-19 infection
- Author
-
Román, Juan León, Vergara, Ander, Agraz, Irene, García-Carro, Clara, Bermejo, Sheila, Gabaldón, Alejandra, and Soler, María José
- Published
- 2021
- Full Text
- View/download PDF
17. COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease?
- Author
-
León-Román, Juan, Agraz, Irene, Vergara, Ander, Ramos, Natalia, Toapanta, Nestor, García-Carro, Clara, Gabaldón, Alejandra, Bury, Roxana, Bermejo, Sheila, Bestard, Oriol, and Soler, María José
- Subjects
COVID-19 ,INTERSTITIAL nephritis ,SARS-CoV-2 ,COVID-19 pandemic ,ACUTE kidney failure ,VIRAL tropism - Abstract
Novel coronavirus disease infection (coronavirus disease 2019, COVID-19) was declared a global pandemic in March 2020 and since then has become a major public health problem. The prevalence of COVID-19 infection and acute kidney injury (AKI) is variable depending on several factors such as race/ethnicity and severity of illness. The pathophysiology of renal involvement in COVID-19 infection is not entirely clear, but it could be in part explained by the viral tropism in the kidney parenchyma. AKI in COVID-19 infection can be either by direct invasion of the virus or as a consequence of immunologic response. Diverse studies have focused on the effect of COVID-19 on glomerulonephritis (GN) patients or the 'novo' GN; however, the effect of COVID-19 in acute tubulointerstitial nephritis (ATIN) has been scarcely studied. In this article, we present five cases with different spectrums of COVID-19 infection and ATIN that may suggest that recent diagnosis of ATIN is accompanied by a worse clinical prognosis in comparison with long-term diagnosed ATIN. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. SARS-CoV-2 infection in patients with chronic kidney disease on haemodialysis. Evolution of SARS-CoV-2 CRP
- Author
-
Zúñiga, José, Toapanta, Néstor, Ramos, Natalia, Caparros, Sonia, León-Roman, Juan, Azancot, María, Garcia-Carro, Clara, Espinel, Eugenia, Seron, Daniel, and Soler, María José
- Published
- 2021
- Full Text
- View/download PDF
19. Antimyeloperoxidase and proteinase 3 antibodies for nephritis flare prediction in ANCA-associated-vasculitis
- Author
-
Rodríguez, Eva, Latzke, Belén, Sierra Carpio, Milagros, Romera, Ana María, Siedel, Diego, Agraz, Irene, Soler, María José, García Carro, Clara, Draibe, Juliana, Prada, Francisco José de la, Villacorta, Javier, Buxeda, Anna, Sierra Ochoa, Adriana, Lozano, Inés, Durán, Xavier, Barrios Barrera, Clara, Pascual, Julio (Pascual Santos), and Spanish Group for the Study of Glomerular Diseases (GLOSEN)
- Subjects
Proteinase-3 antibodies ,Pauci-immune necrotizing glomerulonephritis flare ,Myeloperoxidase antibodies ,ANCA-associated vasculitides - Abstract
Background: The value of myeloperoxidase and proteinase 3 antibodies titers in the assessment of renal disease activity and flare prediction in patients with ANCA-associated-vasculitis (AAV) is not well-known. Methods: Retrospective study including 113 AVV patients with a renal biopsy-proven pauci-immune necrotizing glomerulonephritis from seven Spanish hospitals. The main inclusion criteria were assessment of MPO antibodies (MPOab) using multiplex flow immunoassay and PR3 antibodies (PR3ab) measurements using immunoassay chemiluminescence with an identical range of values for all participating centers. Results: Serum MPOab, 3 ± 1.2 months before relapse, was higher in patients who relapsed (19.2 ± 12.2 vs 3.2 ± 5.1 AI, p < 0.001). The discrimination value of MPOab 3 months before renal relapse had an AUC of 0.82 (95%CI 0.73-0.92; p < 0.001). ΔMPOab (change in antibodies titration 6 months before relapse) was higher in patients who relapsed [8.3 ± 12 vs 0.9 ± 3.1 AI, p = 0.001) (AI; antibody index unit). The discrimination value of ΔMPO had an AUC of 0.76 (95%CI 0.63-0.88; p < 0.001). The positive predictive value of renal relapse in PR3 patients is 100% and the negative predictive value of renal relapse in patients with PR3 positive titers is 57.1%. Serum PR3ab was higher in patients who relapsed 2.8 ± 1.4 months before relapse (58.6 ± 24.6 vs 2.0 ± 0.6 AI, p < 0.001). Conclusions: MPO antibody level monitorization using multiplex flow immunoassay and PR3 measurements using immunoassay chemiluminescence are useful and sensitive tools for the prediction of renal relapse in the follow-up of AAV patients with renal disease, and relevant surrogate markers of renal disease activity.
- Published
- 2021
20. Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study.
- Author
-
Bolufer, Mónica, García-Carro, Clara, Blasco, Miquel, Quintana, Luis F., Shabaka, Amir, Rabasco, Cristina, Draibe, Juliana, Merino, Ana, Melero, María Rosa, Alonso, Fabiola, Buxeda, Anna, Batalha, Paula, Visús, Maria Teresa, and Soler, Maria José
- Abstract
Background: Currently, following the new advances in cancer treatments and the increasing prevalence of kidney disease in the population, more kidney biopsies are being performed. The aim of our study is to analyze clinical and histological characteristics of patients with active solid organ malignancy who underwent kidney biopsy. This is a multi-center collaborative retrospective study supported by groups GLOSEN/Onconephrology from the Spanish Society of Nephrology. Clinical, demographical and histological data were collected. Results: A total of 148 patients with cancer who underwent a kidney biopsy from 12 hospitals were included. 64.3% men and mean age of 66.9 years old. The indications for biopsy were acute renal injury (67.1%), proteinuria (17.1%), exacerbated chronic kidney disease (8.2%), and chronic kidney disease (7.5%). Most frequent malignances were lung (29.1%) and abdominal (25%), with 49.7% metastatic cancer. As oncospecific treatment, 28% received chemotherapy, 29.3% immunotherapy, 19.3% specific therapies, and 2.1% conservative treatment. At the time of kidney biopsy, median creatinine was of 2.58 mg/dL [1.81–4.1 (IQ 25–75)], median urine protein-to-creatinine ratio of 700 mg/g [256–2463 (IQ 25–75)] and 53.1% presented hematuria. The most frequent renal biopsy diagnoses were: acute interstitial nephritis (39.9%), acute tubular necrosis (8.8%), IgA nephropathy (7.4%) and membranous nephropathy (6.1%). Median follow-up was 15.2 months [5.7–31.4 (IQ 25–75)]. Conclusions: There is a new trend in kidney disease and cancer patients in terms of diagnosis and treatment. Acute interstitial nephritis has established itself as the most common kidney injury in patients with cancer who underwent a kidney biopsy. Renal biopsy is a valuable tool for diagnosis, treatment, and prognosis of solid organ cancer patients with kidney damage. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors.
- Author
-
García-Carro, Clara, Bolufer, Mónica, Bury, Roxana, Castañeda, Zaira, Muñoz, Eva, Felip, Enriqueta, Lorente, David, Carreras, María Josep, Gabaldon, Alejandra, Agraz, Irene, Serón, Daniel, and Soler, María José
- Subjects
- *
INJURY risk factors , *ACUTE kidney failure , *CANCER patients , *DISEASE risk factors ,MORTALITY risk factors - Abstract
Background Checkpoint inhibitors (CPIs) have drastically improved metastatic cancer outcomes. However, immunotherapy is associated with multiple toxicities, including acute kidney injury (AKI). Data about CPI-related AKI are limited. Our aim was to determine risk factors for CPI-related AKI as well as its clinical characteristics and its impact on mortality in patients undergoing immunotherapy. Methods All patients under CPI at our centre between March 2018 and May 2019 and with a follow-up through April 2020 were included. Demographic, clinical and laboratory data were collected. AKI was defined according to the Kidney Disease: Improving Global Outcomes guidelines. We performed a logistic regression model to identify independent risk factors for AKI and actuarial survival analysis to establish risk factors for mortality in this population. Results A total of 759 patients were included, with a median age of 64 years. A total of 59% were men and baseline median creatinine was 0.80 mg/dL. The most frequent malignancy was lung cancer and 56% were receiving anti-programmed death protein 1 (PD-1). About 15.5% developed AKI during the follow-up. Age and baseline kidney function were identified as independent risk factors for CPI-related AKI. At the end of follow-up, 52.3% of patients had died. The type of cancer (not melanoma, lung or urogenital malignance), type of CPI (not cytotoxic T-lymphocyte-associated protein 4, PD-1, programmed death-ligand 1 or their combination) and the presence of an episode of AKI were identified as risk factors for mortality. Conclusions A total of 15.5% of patients under immunotherapy presented with AKI. A single AKI episode was identified as an independent risk factor for mortality in these patients and age and baseline renal function were risk factors for the development of AKI. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Anti-myeloperoxidase and proteinase 3 antibodies for nephritis flare prediction in anti-neutrophil cytoplasmic antibody–associated vasculitis.
- Author
-
Rodríguez, Eva, Latzke, Belén, Sierra, Milagros, Romera, Ana María, Siedel, Diego, Agraz, Irene, Soler, María José, García-Carro, Clara, Draibe, Juliana, Prada, Francisco José de la, Villacorta, Javier, Buxeda, Anna, Sierra-Ochoa, Adriana, Lozano, Inés, Durán, Xavier, Barrios, Clara, and Pascual, Julio
- Subjects
LUPUS nephritis ,RECEIVER operating characteristic curves ,PROTEINASES ,IMMUNOGLOBULINS ,NEPHRITIS ,CHEMILUMINESCENCE immunoassay - Abstract
Background The value of myeloperoxidase (MPO) and proteinase 3 (PR3) antibody titres in the assessment of renal disease activity and flare prediction in patients with anti-neutrophil cytoplasmic antibody–associated vasculitis (AAV) is not well known. Methods We performed a retrospective study including 113 AVV patients with renal biopsy–proven pauci-immune necrotizing glomerulonephritis from seven Spanish hospitals. The main inclusion criteria were assessment of MPO antibodies using multiplex flow immunoassay and PR3 antibody measurements using immunoassay chemiluminescence with an identical range of values for all participating centres. Results Serum MPO antibodies 3 ± 1.2 months before relapse were higher in patients who relapsed [19.2 ± 12.2 versus 3.2 ± 5.1 antibody index (AI); P < 0.001]. The discrimination value of MPO antibodies 3 months before renal relapse had an area under the receiver operating characteristics curve (AUC) of 0.82 [95% confidence interval (CI) 0.73–0.92; P < 0.001]. ΔMPO antibodies (change in antibodies titration 6 months before relapse) were higher in patients who relapsed (8.3 ± 12 versus 0.9 ± 3.1 AI; P = 0.001). The discrimination value of ΔMPO had an AUC of 0.76 (95% CI 0.63–0.88; P < 0.001). The positive predictive value of renal relapse in PR3 patients is 100% and the negative predictive value of renal relapse in patients with PR3-positive titres is 57.1%. Serum PR3 antibodies were higher in patients who relapsed 2.8 ± 1.4 months before relapse (58.6 ± 24.6 versus 2.0 ± 0.6 AI; P < 0.001). Conclusions MPO level monitoring using multiplex flow immunoassay and PR3 measurements using immunoassay chemiluminescence are useful and sensitive tools for the prediction of renal relapse in the follow-up of AAV patients with renal disease and relevant surrogate markers of renal disease activity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Challenges in primary focal segmental glomerulosclerosis diagnosis : from the diagnostic algorithm to novel biomarkers
- Author
-
Jacobs-Cachá, Conxita, Vergara, Ander, García-Carro, Clara, Agraz Pamplona, Irene, Toapanta, Néstor, Ariceta Iraola, Gema, Moreso, Francesc, Serón, Daniel, López-Hellín, Joan, Soler, María José, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Jacobs-Cachá C, García-Carro C, Agraz I, Moreso F, Serón D, Soler MJ] Grup de Recerca en Nefrologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vergara A, Toapanta-Gaibor N] Grup de Recerca en Nefrologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ariceta G] Red de Investigaciones Renales (RedInRen), Madrid, Spain. Servei de Nefrologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [López-Hellín J] Red de Investigaciones Renales (RedInRen), Madrid, Spain. Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca en Bioquímica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
diagnosis algorithm ,030232 urology & nephrology ,Focal segmental glomerulosclerosis ,Disease ,030204 cardiovascular system & hematology ,Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores] ,urologic and male genital diseases ,Surgical Procedures, Operative::Surgical Procedures, Operative::Urogenital Surgical Procedures::Urologic Surgical Procedures::Kidney Transplantation [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,03 medical and health sciences ,0302 clinical medicine ,Idiopathic nephrotic syndrome ,Glomerulopathy ,Ronyons - Malalties - Diagnòstic ,Other subheadings::Other subheadings::/adverse effects [Other subheadings] ,medicine ,Minimal change disease ,AcademicSubjects/MED00340 ,Otros calificadores::/terapia [Otros calificadores] ,Kidney transplantation ,CKJ Reviews ,focal segmental glomerulosclerosis ,Transplantation ,Kidney ,business.industry ,Primary Focal Segmental Glomerulosclerosis ,urogenital system ,Male Urogenital Diseases::Urologic Diseases::Kidney Diseases [DISEASES] ,Primary FSGS ,biomarkers ,Other subheadings::/therapy [Other subheadings] ,medicine.disease ,female genital diseases and pregnancy complications ,medicine.anatomical_structure ,intervenciones quirúrgicas::trasplante::trasplante de órganos::intervenciones quirúrgicas::trasplante de riñón [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Nephrology ,idiopathic nephrotic syndrome ,primary FSGS ,business ,enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales [ENFERMEDADES] ,Nephrotic syndrome ,Algorithm ,Diagnosis algorithm ,Ronyons - Trasplantació - Complicacions ,Ronyons - Malalties - Tractament ,Biomarkers - Abstract
Biomarcadors; Algoritme de diagnosi; Glomerulosclerosi segmentària focal Biomarcadores; Algoritmo de diagnóstico; Glomeruloesclerosis segmentaria focal Biomarkers; Diagnosis algorithm; Focal segmental glomerulosclerosis Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS. The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, Instituto de Salud Carlos III (PI17/00257, PI18/01704 and PI18/01832) and REDinREN (RD16/0009/0030).
- Published
- 2020
24. COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease.
- Author
-
Román, Juan León, García-Carro, Clara, Agraz, Irene, Toapanta, Nestor, Vergara, Ander, Gabaldón, Alejandra, Torres, Irina, Bury, Roxana, Baldallo, Cinthia, Serón, Daniel, and Soler, María José
- Subjects
- *
COVID-19 , *KIDNEY transplantation , *KIDNEY diseases , *CARDIOVASCULAR diseases , *RENAL biopsy , *SYMPTOMS ,MORTALITY risk factors - Abstract
Introduction: Chronic kidney disease (CKD) patients infected with COVID-19 are at risk of serious complications such as hospitalization and death. The prognosis and lethality of COVID-19 infection in patients with established kidney disease has not been widely studied. Methods: Data included patients who underwent kidney biopsy at the Vall d'Hebron Hospital between January 2013 and February 2020 with COVID-19 diagnosis during the period from March 1 to May 15, 2020. Results: Thirty-nine (7%) patients were diagnosed with COVID-19 infection. Mean age was 63 ± 15 years and 48.7% were male. Hypertension was present in 79.5%, CKD without renal replacement therapy in 76.9%, and cardiovascular disease in 64.1%. Nasopharyngeal swab was performed in 26 patients; older (p = 0.01), hypertensive (p = 0.005), and immunosuppressed (p = 0.01) patients, those using RAS-blocking drugs (p = 0.04), and those with gastrointestinal symptoms (p = 0.02) were more likely to be tested for CO-VID-19. Twenty-two patients required hospitalization and 15.4% died. In bivariate analysis, mortality was associated with older age (p = 0.03), cardiovascular disease (p = 0.05), chronic obstructive pulmonary disease (p = 0.05), and low hemoglobin levels (p = 0.006). Adjusted Cox regression showed that low hemoglobin levels at admission had 1.81 greater risk of mortality. Conclusions: Patients with CO-VID-19 infection and kidney disease confirmed by kidney biopsy presented a mortality of 15.4%. Swab test for COVID-19 was more likely to be performed in older, hypertensive, and immunosuppressed patients, those using RAS-blocking drugs, and those with gastrointestinal symptoms. Low hemoglobin is a risk factor for mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience.
- Author
-
Oleas, Diana, Bolufer, Mónica, Agraz, Irene, Felip, Enriqueta, Muñoz, Eva, Gabaldón, Alejandra, Bury, Roxana, Espinel, Eugenia, Serón, Daniel, García-Carro, Clara, and Soler, María José
- Subjects
IMMUNE checkpoint inhibitors ,INTERSTITIAL nephritis ,DRUG side effects ,ACUTE kidney failure ,RENAL biopsy ,CHRONIC kidney failure - Abstract
Background Checkpoint inhibitors (CPIs) are used to treat solid organ metastatic malignancies. They act by triggering a vigorous immune response against tumoural cells, preventing their proliferation and metastasis. However, this is not a selective response and can cause immune-related adverse events (irAEs). The kidney can potentially be damaged, with an incidence of irAEs of 1–4%. The most frequent type of toxicity described is acute interstitial nephritis (AIN). Methods We conducted a study of patients with solid organ metastatic malignancies treated with immunotherapy who developed acute renal injury and underwent kidney biopsy in the last 14 months at the Vall d'Hebron University Hospital. Results In all, 826 solid organ malignancies were treated with immunotherapy in our centre, 125 of them (15.1%) developed acute kidney injury (AKI), 23 (18.4% of AKI) visited the nephrology department and 8 underwent kidney biopsy. The most frequent malignancy was lung cancer, in five patients (62%), followed by two patients (25%) with melanoma and one patient (12%) with pancreatic cancer. Four patients (50%) had already received previous oncological therapy, and for the remaining four patients (50%), CPI was the first-line therapy. Five patients (62%) were treated with anti-programmed cell death protein 1, three patients (37%) received anti-programmed death ligand 1 and two (25%) patients were treated in combination with anti-cytotoxic T-lymphocyte antigen 4. The time between the start of CPI and the onset of the AKI ranged from 2 to 11 months. The most frequent urine findings were subnephrotic-range proteinuria, with a mean protein:creatinine ratio of 544 mg/g (standard deviation 147) and eosinophiluria. All patients were biopsied after being diagnosed with AIN. Three patients (37%) received treatment with pulses of methylprednisolone 250–500 mg/day and five patients (62%) received prednisone 1 mg/kg/day. Seven patients (87%) experienced recovery of kidney function and one patient (12%) progressed to chronic kidney disease. Conclusions We report on eight patients with CPI-related AIN diagnosed in the last 14 months at our centre. The novel immunotherapy treatment of metastatic solid organ malignancies carries a higher risk of irAEs. The kidney is one of the most commonly affected organs, frequently presenting as an AIN and exhibiting a favourable response to steroid treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?
- Author
-
Draibe, Juliana B, García-Carro, Clara, Martinez-Valenzuela, Laura, Agraz, Irene, Fulladosa, Xavier, Bolufer, Monica, Tango, Ariel, Torras, Joan, and Soler, María José
- Subjects
- *
DRUG side effects , *ACUTE kidney failure , *NEPHRITIS , *IPILIMUMAB , *IMMUNE checkpoint inhibitors , *INTERSTITIAL nephritis , *DIAGNOSIS - Abstract
Background The incidence of acute tubulointerstitial nephritis (ATIN) related to drugs has dramatically increased over recent years. A new subtype of ATIN, apparently different from classical drug-related ATIN, has emerged that has been related to the administration of immune checkpoint inhibitors (ICIs). We investigated these differences between ICI-related ATIN (ICI ATIN) and non-ICI-related ATIN in terms of clinical features, response to treatment with steroids and the evolution of kidney function. Methods A total of 47 patients diagnosed with ATIN from two centres were recruited. Of these, 13 patients presented with ATIN during ICI treatment and 34 were diagnosed with ATIN attributed to other drugs. The main demographic, clinical and analytical variables such as gender, age and current medication were recorded. The type of malignancy, oncological treatment, ICI dose and presence of extrarenal immune-related adverse events were also reviewed. Renal biopsy diagnosis, time to drug withdrawal and ATIN-specific treatment, as well as laboratory data during follow-up, were also studied. Results Patients diagnosed with ICI ATIN presented with lower creatinine (ICI ATIN 3.8 ± 1.03 versus classical ATIN 5.98 ± 4.15 mg/dL, P = 0.007) at diagnosis and higher urinary leucocyte counts (ICI ATIN 263.2 ± 418.04 versus classical ATIN 133.55 ± 284.62, P = 0.048) compared with patients with non-ICI-related ATIN. Time from initiation of the culprit drug to ATIN diagnosis was longer in patients with ICI ATIN than in those with classical ATIN (197.07 ± 184.99 versus 114.4 ± 352.16 days, P = 0.006). In addition, during follow-up, the slope of decreasing creatinine over time was lower for ICI ATIN compared with non-ICI-related ATIN. Conclusions In this study, we analysed differences between ICI ATIN and classical ATIN. We found that patients with ICI ATIN presented with a larger latency period after culprit drug initiation, milder acute kidney injury and slower creatinine amelioration compared with those with classical ATIN. These results may, in part, be ascribed to potential differences in the pathological mechanisms involved in ATIN development, suggesting that ICI and classical ATIN may be different diseases with similar renal histologies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers.
- Author
-
Jacobs-Cachá, Conxita, Vergara, Ander, García-Carro, Clara, Agraz, Irene, Toapanta-Gaibor, Nestor, Ariceta, Gema, Moreso, Francesc, Serón, Daniel, López-Hellín, Joan, and Soler, Maria José
- Subjects
FOCAL segmental glomerulosclerosis ,DIAGNOSIS ,KIDNEY diseases ,CHRONIC kidney failure ,BIOMARKERS ,KIDNEY transplantation - Abstract
Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Diabetes and renal disease—should we biopsy?
- Author
-
Bermejo, Sheila, García-Carro, Clara, and Soler, María José
- Subjects
- *
KIDNEY diseases , *DIABETIC nephropathies , *IGA glomerulonephritis , *TYPE 2 diabetes , *KIDNEY glomerulus diseases , *RENAL biopsy , *BIOPSY - Published
- 2021
- Full Text
- View/download PDF
29. Inflammation and Atherosclerosis Are Associated With Hypertension in Kidney Transplant Recipients.
- Author
-
Azancot, Maria A., Ramos, Natalia, Torres, Irina B., García‐Carro, Clara, Romero, Katheryne, Espinel, Eugenia, Moreso, Francesc, Seron, Daniel, and García-Carro, Clara
- Abstract
The aim of the current study was to evaluate risk factors associated with hypertension in kidney transplant recipients. The authors recruited 92 consecutive kidney transplant recipients and 30 age-matched patients with chronic kidney disease without history of cardiovascular events. Twenty-four-hour ambulatory blood pressure monitoring, pulse wave velocity, and carotid ultrasound were performed. Serum levels of log-transformed interleukin 6 (Log IL-6), soluble tumor necrosis factor receptor 2, and intercellular adhesion molecule 1 were determined. Twenty-four-hour systolic blood pressure (SBP) (P=.0001), Log IL-6 (P=.011), and total number of carotid plaques (P=.013) were higher, while the percentage decline of SBP from day to night was lower in kidney transplant recipients (P=.003). Independent predictors of 24-hour SBP were urinary protein/creatinine ratio and circulating monocytes (P=.001), while Log IL-6, serum creatinine, and total number of carotid plaques (P=.0001) were independent predictors of percentage decline of SBP from day to night. These results suggest that subclinical atherosclerosis and systemic inflammation are associated with hypertension after transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
30. Kidney allograft subclinical rejection modulates systemic inflammation measured by C‐reactive protein at 1 year after transplantation.
- Author
-
García‐Carro, Clara, Dörje, Christina, Åsberg, Anders, Midtvedt, Karsten, Scott, Helge, Reinholt, Finn P., Holdaas, Hallvard, Reisæter, Anna V., and Seron, Daniel
- Subjects
- *
KIDNEY diseases , *HOMOGRAFTS , *MONONUCLEAR leukocytes , *INFLAMMATION , *BIOPSY - Abstract
Abstract: Kidney allograft inflammation is associated with proinflammatory modifications of peripheral blood mononuclear cells, suggesting that renal inflammation contributes to systemic inflammation. Thus, the aim of this study was to evaluate the relationship between subclinical inflammation in surveillance biopsies performed at 1 year and systemic inflammation assessed by C‐reactive protein (CRP) levels at the time of biopsy. We analyzed 544 surveillance biopsies performed at 1 year that were classified as normal (n = 368), borderline (n = 148), or subclinical rejection (SCR) (n = 28). CRP levels were divided into quartiles. Patients in 1st, 2nd, and 3rd quartile were classified as low CRP (n = 408) and patients in the 4th quartile as high CRP (n = 136). Univariate analysis showed that the proportion of patients with SCR was higher in the high CRP group (10.3% vs 3.4%,
P = 0.0067). Multivariate analysis showed that independent predictors of high CRP were body mass index (odds ratio [OR] 1.072 and 95% confidence interval [CI] 1.027‐1.119), a positive urine culture at the day of the biopsy (OR 2.760 and 95% CI 1.205‐6.323), and the presence of SCR at 1‐year surveillance biopsy (OR 7.260 and 95% CI 3.530‐14.935). In summary, we describe that subclinical acute rejection constitutes an independent predictor of systemic inflammation as measured by CRP. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
31. Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies.
- Author
-
García-Carro, Clara, Dörje, Christina, Åsberg, Anders, Midtvedt, Karsten, Scott, Helge, Reinholt, Finn P., Holdaas, Hallvard, Seron, Daniel, and Reisæter, Anna V.
- Published
- 2017
- Full Text
- View/download PDF
32. Safety of Obtaining an Extra Biobank Kidney Biopsy Core.
- Author
-
Bermejo, Sheila, García-Carro, Clara, Mast, Richard, Vergara, Ander, Agraz, Irene, León, Juan Carlos, Bolufer, Monica, Gabaldon, Maria-Alejandra, Serón, Daniel, Bestard, Oriol, and Soler, Maria Jose
- Subjects
- *
RENAL biopsy , *FISTULA , *ARTERIOVENOUS fistula , *BLOOD transfusion , *PROTHROMBIN time - Abstract
Background and objectives: Kidney biopsy (KB) is the "gold standard" for the diagnosis of nephropathies and it is a diagnostic tool that presents a low rate of complications. Nowadays, biobank collections of renal tissue of patients with proven renal pathology are essential for research in nephrology. To provide enough tissue for the biobank collection, it is usually needed to obtain an extra kidney core at the time of kidney biopsy. The objective of our study is to evaluate the complications after KB and to analyze whether obtaining an extra core increases the risk of complications. Material and methods: Prospective observational study of KBs performed at Vall d'Hebron Hospital between 2019 and 2020. All patients who accepted to participate to our research biobank of native kidney biopsies were included to the study. Clinical and laboratory data were reviewed and we studied risk factors associated with complications. Results: A total of 221 patients were included, mean age 56.6 (±16.8) years, 130 (58.8%) were men, creatinine was 2.24 (±1.94) mg/dL, proteinuria 1.56 (0.506–3.590) g/24 h, hemoglobin 12.03 (±2.3) g/dL, INR 0.99 (±0.1), and prothrombin time (PT) 11.86 (±1.2) s. A total of 38 patients (17.2%) presented complications associated with the procedure: 13.1% were minor complications, 11.3% (n = 25) required blood transfusion, 1.4% (n = 3) had severe hematomas, 2.3% (n = 5) required embolization, and 0.5% (n = 1) presented arterio-venous fistula. An increased risk for complication was independently associated with obtaining a single kidney core (vs. 2 and 3 cores) (p = 0.021). Conclusions: KB is an invasive and safe procedure with a low percentage of complications. Obtaining an extra kidney core for research does not increase the risk of complications during the intervention, which remains low in concordance with previously published reports. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR.
- Author
-
García-Carro, Clara, Vergara, Ander, Bermejo, Sheila, Azancot, María A., Sánchez-Fructuoso, Ana I., Sánchez de la Nieta, M. Dolores, Agraz, Irene, and Soler, María José
- Subjects
- *
DIABETIC nephropathies , *TYPE 2 diabetes , *DISEASE progression , *ALBUMINURIA , *DIAGNOSIS , *GLOMERULAR filtration rate - Abstract
Diabetic kidney disease (DKD) is one of the most relevant complications of type 2 diabetes and dramatically increases the cardiovascular risk in these patients. Currently, DKD is severely infra-diagnosed, or its diagnosis is usually made at advanced stages of the disease. During the last decade, new drugs have demonstrated a beneficial effect in terms of cardiovascular and renal protection in type 2 diabetes, supporting the crucial role of an early DKD diagnosis to permit the use of new available therapeutic strategies. Moreover, cardiovascular and renal outcome trials, developed to study these new drugs, are based on diverse cardiovascular and renal simple and composite endpoints, which makes difficult their interpretation and the comparison between them. In this article, DKD diagnosis is reviewed, focusing on albuminuria and the recommendations for glomerular filtration rate measurement. Furthermore, cardiovascular and renal endpoints used in classical and recent cardiovascular outcome trials are assessed in a pragmatic way. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Urinary Extracellular Vesicles for Diabetic Kidney Disease Diagnosis.
- Author
-
Saenz-Pipaon, Goren, Echeverria, Saioa, Orbe, Josune, Roncal, Carmen, Mora-Gutierrez, José María, Soler, María José, Garcia-Fernandez, Nuria, and García-Carro, Clara
- Subjects
DIABETIC nephropathies ,KIDNEY disease diagnosis ,EXTRACELLULAR vesicles ,CHRONIC kidney failure ,DRUG target ,KIDNEY diseases - Abstract
Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in developed countries, affecting more than 40% of diabetes mellitus (DM) patients. DKD pathogenesis is multifactorial leading to a clinical presentation characterized by proteinuria, hypertension, and a gradual reduction in kidney function, accompanied by a high incidence of cardiovascular (CV) events and mortality. Unlike other diabetes-related complications, DKD prevalence has failed to decline over the past 30 years, becoming a growing socioeconomic burden. Treatments controlling glucose levels, albuminuria and blood pressure may slow down DKD evolution and reduce CV events, but are not able to completely halt its progression. Moreover, one in five patients with diabetes develop DKD in the absence of albuminuria, and in others nephropathy goes unrecognized at the time of diagnosis, urging to find novel noninvasive and more precise early diagnosis and prognosis biomarkers and therapeutic targets for these patient subgroups. Extracellular vesicles (EVs), especially urinary (u)EVs, have emerged as an alternative for this purpose, as changes in their numbers and composition have been reported in clinical conditions involving DM and renal diseases. In this review, we will summarize the current knowledge on the role of (u)EVs in DKD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Revisiting Experimental Models of Diabetic Nephropathy.
- Author
-
Giralt-López, Anna, Molina-Van den Bosch, Mireia, Vergara, Ander, García-Carro, Clara, Seron, Daniel, Jacobs-Cachá, Conxita, and Soler, Maria José
- Subjects
DIABETIC nephropathies ,PEOPLE with diabetes ,CHRONIC kidney failure ,KIDNEY diseases ,GLOMERULAR filtration rate ,BASAL lamina - Abstract
Diabetes prevalence is constantly increasing and, nowadays, it affects more than 350 million people worldwide. Therefore, the prevalence of diabetic nephropathy (DN) has also increased, becoming the main cause of end-stage renal disease (ESRD) in the developed world. DN is characterized by albuminuria, a decline in glomerular filtration rate (GFR), hypertension, mesangial matrix expansion, glomerular basement membrane thickening, and tubulointerstitial fibrosis. The therapeutic advances in the last years have been able to modify and delay the natural course of diabetic kidney disease (DKD). Nevertheless, there is still an urgent need to characterize the pathways that are involved in DN, identify risk biomarkers and prevent kidney failure in diabetic patients. Rodent models provide valuable information regarding how DN is set and its progression through time. Despite the utility of these models, kidney disease progression depends on the diabetes induction method and susceptibility to diabetes of each experimental strain. The classical DN murine models (Streptozotocin-induced, Akita, or obese type 2 models) do not develop all of the typical DN features. For this reason, many models have been crossed to a susceptible genetic background. Knockout and transgenic strains have also been created to generate more robust models. In this review, we will focus on the description of the new DN rodent models and, additionally, we will provide an overview of the available methods for renal phenotyping. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists.
- Author
-
Górriz, José Luis, Soler, María José, Navarro-González, Juan F., García-Carro, Clara, Puchades, María Jesús, D'Marco, Luis, Martínez Castelao, Alberto, Fernández-Fernández, Beatriz, Ortiz, Alberto, Górriz-Zambrano, Carmen, Navarro-Pérez, Jorge, and Gorgojo-Martinez, Juan José
- Subjects
GLUCAGON-like peptide-1 agonists ,GLUCAGON-like peptide-1 receptor ,CARDIOVASCULAR diseases risk factors ,TYPE 2 diabetes ,DIABETIC nephropathies ,NEPHROLOGISTS - Abstract
Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD. In this regard, GLP-1RA offer the potential for adequate glycemic control in multiple stages of DKD without an increased risk of hypoglycemia, preventing the onset of macroalbuminuria and slowing the decline of glomerular filtration rate (GFR) in diabetic patients, also bringing additional benefit in weight reduction, cardiovascular and other kidney outcomes. Results from ongoing trials are pending to assess the impact of GLP-1RA treatments on primary kidney endpoints in DKD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes.
- Author
-
García-Carro, Clara, Vergara, Ander, Agraz, Irene, Jacobs-Cachá, Conxita, Espinel, Eugenia, Seron, Daniel, and Soler, María José
- Subjects
- *
TYPE 2 diabetes , *GLUCAGON-like peptide-1 receptor , *GLUCAGON-like peptide-1 agonists , *DIABETIC nephropathies , *CD26 antigen - Abstract
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. However, this strategy only partially covered the DKD progression. Thus, new strategies for reno-cardiovascular protection in type 2 diabetic patients are urgently needed. In the last few years, hypoglycaemic drugs, such as sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, demonstrated a cardioprotective effect, mainly in terms of decreasing hospitalization for heart failure and cardiovascular death in type 2 diabetic patients. In addition, these drugs also demonstrated a clear renoprotective effect by delaying DKD progression and decreasing albuminuria. Another hypoglycaemic drug class, dipeptidyl peptidase 4 inhibitors, has been approved for its use in patients with advanced chronic kidney disease, avoiding, in part, the need for insulinization in this group of DKD patients. Studies in diabetic and non-diabetic experimental models suggest that these drugs may exert their reno-cardiovascular protective effect by glucose and non-glucose dependent mechanisms. This review focuses on newly demonstrated strategies that have shown reno-cardiovascular benefits in type 2 diabetes and that may change diabetes management algorithms. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
38. Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model.
- Author
-
Vergara, Ander, Jacobs-Cachá, Conxita, Molina-Van den Bosch, Mireia, Domínguez-Báez, Pamela, Benito, Begoña, García-Carro, Clara, Serón, Daniel, and Soler, María José
- Subjects
- *
ANGIOTENSIN converting enzyme , *COVID-19 , *RESPIRATORY organs , *ACE inhibitors , *RENIN-angiotensin system , *RAMIPRIL - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19). The main organ affected in this infection is the lung and the virus uses the angiotensin-converting enzyme 2 (ACE2) as a receptor to enter the target cells. In this context, a controversy raised regarding the use of renin-angiotensin system (RAAS) blockers, as these drugs might increase ACE2 expression in some tissues and potentially increase the risk for SARS-CoV-2 infection. This is specially concerning in diabetic patients as diabetes is a risk factor for COVID-19. 12-week old diabetic mice (db/db) were treated with ramipril, or vehicle control for 8 weeks. Non-diabetic db/m mice were included as controls. ACE2 expression and activity were studied in lung, kidney and heart of these animals. Kidney ACE2 activity was increased in the db/db mice as compared to the db/m (143.2% ± 23% vs 100% ± 22.3%, p = 0.004), whereas ramipril had no significant effect. In the lung, no differences were found in ACE2 when comparing db/db mice to db/m and ramipril also had no significant effect. In the heart, diabetes decreased ACE2 activity (83% ± 16.8%, vs 100% ± 23.1% p = 0.02), and ramipril increased ACE2 significantly (83% ± 16.8% vs 98.2% ± 15%, p = 0.04). In a mouse model of type 2 diabetes, ramipril had no significant effect on ACE2 activity in either kidneys or in the lungs. Therefore, it is unlikely that RAAS blockers or at least angiotensin-converting enzyme inhibitors increase the risk of SARS-CoV-2 infection through increasing ACE2. • The Angiotensin Converting Enzyme 2 (ACE2) is the main receptor for the SARS-CoV-2, the virus that causes COVID-19. • It has been suggested that RAAS blockade may increase the expression of ACE2 and the risk of SARS-CoV-2 infection, which is specially concerning in diabetic patients. • In kidney, ACE2 was found increased in db/db as compared to the non-diabetic littermates. Ramipril normalized ACE2 gene expression but had no effect on ACE2 activity. • In lung, no differences were found in ACE2 when comparing db/db mice to db/m and Ramipril had no effect. • RAAS blockade in db/db did not induce increase of the levels of ACE2 in the kidney and the lung which suggests that it will not exert a deleterious effect on COVID-19 patients with diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry.
- Author
-
Waldman M, Soler MJ, García-Carro C, Lightstone L, Turner-Stokes T, Griffith M, Torras J, Martinez Valenzuela L, Bestard O, Geddes C, Flossmann O, Budge KL, Cantarelli C, Fiaccadori E, Delsante M, Morales E, Gutierrez E, Niño-Cruz JA, Martinez-Rueda AJ, Comai G, Bini C, La Manna G, Slon MF, Manrique J, Avello A, Fernandez-Prado R, Ortiz A, Marinaki S, Martin Varas CR, Rabasco Ruiz C, Sierra-Carpio M, García-Agudo R, Fernández Juárez G, Hamilton AJ, Bruchfeld A, Chrysochou C, Howard L, Sinha S, Leach T, Agraz Pamplona I, Maggiore U, and Cravedi P
- Subjects
- Follow-Up Studies, Humans, Registries, SARS-CoV-2, Acute Kidney Injury complications, COVID-19 epidemiology
- Abstract
Background: The acute and long-term effects of severe acute respiratory syndrome coronavirus 2 infection in individuals with GN are still unclear. To address this relevant issue, we created the International Registry of COVID-19 infection in GN., Methods: We collected serial information on kidney-related and -unrelated outcomes from 125 GN patients (63 hospitalized and 62 outpatients) and 83 non-GN hospitalized patients with coronavirus disease 2019 (COVID-19) and a median follow-up period of 6.4 (interquartile range 2.3-9.6) months after diagnosis. We used logistic regression for the analyses of clinical outcomes and linear mixed models for the longitudinal analyses of eGFR. All multiple regression models were adjusted for age, sex, ethnicity, and renin-angiotensin-aldosterone system inhibitor use., Results: After adjustment for pre-COVID-19 eGFR and other confounders, mortality and AKI did not differ between GN patients and controls (adjusted odds ratio for AKI=1.28; 95% confidence interval [CI], 0.46 to 3.60; P =0.64). The main predictor of AKI was pre-COVID-19 eGFR (adjusted odds ratio per 1 SD unit decrease in eGFR=3.04; 95% CI, 1.76 to 5.28; P <0.001). GN patients developing AKI were less likely to recover pre-COVID-19 eGFR compared with controls (adjusted 6-month post-COVID-19 eGFR=0.41; 95% CI, 0.25 to 0.56; times pre-COVID-19 eGFR). Shorter duration of GN diagnosis, higher pre-COVID-19 proteinuria, and diagnosis of focal segmental glomerulosclerosis or minimal change disease were associated with a lower post-COVID-19 eGFR., Conclusions: Pre-COVID-19 eGFR is the main risk factor for AKI regardless of GN diagnosis. However, GN patients are at higher risk of impaired eGFR recovery after COVID-19-associated AKI. These patients (especially those with high baseline proteinuria or a diagnosis of focal segmental glomerulosclerosis or minimal change disease) should be closely monitored not only during the acute phases of COVID-19 but also after its resolution., Competing Interests: O. Bestard reports patents and inventions with Oxford Immunotec and is associate editor of Transplant International and Frontiers in Immunology. A. Bruchfeld reports consultancy agreements with AstraZeneca, Chemocentryx, Fresenius, and Merck; a research grant from AstraZeneca; honoraria from Bayer, Chemocentryx, Fresenius, Merck, and Vifor; and is a member of the ERA-EDTA scientific advisory board 2018–2024, chair of the ERA-EDTA Immunonephrology Working Group, and vice-chair of the Swedish Renal Fund. G. Comai reports honoraria from Alexion, Astellas, and Novartis. P. Cravedi reports honoraria as an advisor for Chinook Therapeutics and is associate editor for the Journal of Nephrology and the American Journal of Transplantation. G. Fernandez Juarez reports research funding from Instituto Salud Calos III and honoraria from Alexion and GSK. E. Fiaccadori is on the editorial board of the Journal of Nephrology and Blood Purification and is a member of the Italian Society of Nephrology and the European Society of Parenteral and Enteral Nutrition. O. Flossmann reports consultancy agreements with Vifor Pharma has other interests/relationships with the British Medical Association, European Vasculitis Society, Renal Association (UK), Royal College of Physicians London, and UK Ireland Vasculitis Society. C. García-Carro reports consultancy agreements with Astellas, AstraZeneca, Boehringer Ingelheim Lilly, Esteve, Novartis and Baxter, Novo Nordisk, and Otsuka; honoraria from Astellas, AstraZeneca, Boehringer Ingelheim Lilly, Esteve, Novartis and Baxter, Novo Nordisk, and Otsuka; and is a scientific advisor for or member of AstraZeneca, Boehringer Ingelheim Lilly, Mundipharma, and Novo Nordisk. M. Griffith reports honoraria from Retrophin’s advisory board. A. J. Hamilton is on the editorial board of the Journal of Kidney Care and is a member of the SONG-Kids Life Participation Expert Working Group. T. Leach reports honoraria from Janssen for conference attendance in 2012 and is a scientific advisor to the National Institute for Health and Care Excellence. L. Lightstone reports consultancy agreements with Achillion, Alexion, AstraZeneca, Aurinia, BMS, GSK, Kezar, Novartis, Pfizer, and Roche; honoraria from Alexion, AstraZeneca, BMS, GSK, and Pfizer; is a scientific advisor or member of EU Exec Lupus Nephritis Trials Network; is on the advisory board of Nature Reviews Nephrology; participates in a speakers’ bureau for Alexion and GSK; is a trustee of Kidney Research UK 2018–2022; is an executive member of the International Society of Nephrology 2021–2023; is deputy chair of Western Regional Board of the International Society of Nephrology; and is a clinical expert representing the Renal Association response to NICE on STA for belimumab in lupus 2020–2021. U. Maggiore reports consultancy agreements with Biotest, Chiesi, GSK, Hansa, Novartis, Sandoz, and Takeda. J. Manrique is a scientific advisor for or member of AstraZeneca, Boehringer, and Viphor Pharma. E. Morales reports consultancy agreements with Alexion, Celgene, Viphor Fresenius, and Vifor Pharma. J.A. Niño-Cruz reports research funding from Pfizer Scientific Institute and participates in a speakers’ bureau for Takeda and Roche. A. Ortiz reports consultancy agreements with Retrophin and Sanofi Genzyme; research funding from AstraZeneca, Mundipharma, and Sanofi Genzyme; honoraria from Advicciene, Alexion, Amgen, Amicus, Astellas, AstraZeneca, Bayer, Chiesi, Fresenius Medical Care, Idorsia, Kyowa Kirin, Menarini, Otsuka, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma; is a member of the Spanish Society of Nephrology; is editor-in-chief of the Clinical Kidney Journal; is on the editorial boards of the Journal of Nephrology, Journal of the American Society of Nephrology, and Peritoneal Dialysis International; is a member of SOMANE and ERA Councils; is on the board of directors for IIS-Fundacion Jimenez Diaz UAM; is on the scientific advisory board of the Dutch Kidney Foundation; honoraria listed above are for speaker engagements: Advicciene, Alexion, Astellas, AstraZeneca, Amicus, Amgen, Bayer, Chiesi, Fresenius Medical Care, Idorsia, Kyowa Kirin, Menarini, Otsuka, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma. S. Sinha reports consultancy agreements with Sanifit; research funding from Amgen, AstraZeneca, and Ethicon; and honoraria from AstraZeneca, Bayer, Napp Pharmaceuticals, Novartis, and Sanofi Genzyme. M.F. Slon-Roblero reports consultancy agreements with Baxter, Fresenius, and Nipro; and honoraria from Baxter, Fresenius, and Nipro. M.J. Soler reports consultancy agreements with AstraZeneca, Bayer, Boehringer, Esteve, Jansen, Mundipharma, Novo Nordisk, Travere, and ICU; research funding from Abbvie and Boehringer; honoraria from AstraZeneca, Boehringer, Esteve, FMC, Jansen, ICU Medical, Mundipharma, Novo Nordisk, Otsuka, and Travere; patents and inventions: U691ES00; is a scientific advisor for or member of BMC Nephrology and Clinical Kidney Journal; is a former member of ERA-EDTA Council; participates in a speakers’ bureau for AstraZeneca, Bayer, Boehringer, Esteve, FMC, Jansen, Mundipharma, Novo Nordisk, and Vifor; is a member of the Sociedad Española de Nefrología and Sociedad Catalana de Nefrologia; and is elected editor-in-chief of the Clinical Kidney Journal. All remaining authors have nothing to disclose., (Copyright © 2022 by the American Society of Nephrology.)
- Published
- 2021
- Full Text
- View/download PDF
40. Focal and segmental glomerulosclerosis associated with COVID-19 infection.
- Author
-
LeónRomán J, Vergara A, Agraz I, García-Carro C, Bermejo S, Gabaldón A, and Soler MJ
- Published
- 2021
- Full Text
- View/download PDF
41. A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management.
- Author
-
García-Carro C, Vergara A, Bermejo S, Azancot MA, Sellarés J, and Soler MJ
- Abstract
Obesity is one of the epidemics of our era. Its prevalence is higher than 30% in the U.S. and it is estimated to increase by 50% in 2030. Obesity is associated with a higher risk of all-cause mortality and it is known to be a cause of chronic kidney disease (CKD). Typically, obesity-related glomerulopathy (ORG) is ascribed to renal hemodynamic changes that lead to hyperfiltration, albuminuria and, finally, impairment in glomerular filtration rate due to glomerulosclerosis. Though not only hemodynamics are responsible for ORG: adipokines could cause local effects on mesangial and tubular cells and podocytes promoting maladaptive responses to hyperfiltration. Furthermore, hypertension and type 2 diabetes mellitus, two conditions generally associated with obesity, are both amplifiers of obesity injury in the renal parenchyma, as well as complications of overweight. As in the native kidney, obesity is also related to worse outcomes in kidney transplantation. Despite its impact in CKD and cardiovascular morbility and mortality, therapeutic strategies to fight against obesity-related CKD were limited for decades to renin-angiotensin blockade and bariatric surgery for patients who accomplished very restrictive criteria. Last years, different drugs have been approved or are under study for the treatment of obesity. Glucagon-like peptide-1 receptor agonists are promising in obesity-related CKD since they have shown benefits in terms of losing weight in obese patients, as well as preventing the onset of macroalbuminuria and slowing the decline of eGFR in type 2 diabetes. These new families of glucose-lowering drugs are a new frontier to be crossed by nephrologists to stop obesity-related CKD progression., Competing Interests: AV reports non-financial support from Mundipharma, outside the submitted work. MS reports personal fees from NovoNordisk, Janssen, AstraZeneca, Fresenius, Mundipharma, Pfizer, Bayer and Vifor, grants and non-financial support from Boehringer, and non-financial support from Eli Lilly and Esteve outside of the submitted work. CG-C has received travel and congress fees support from Astra-Zeneca, Esteve, NovoNordisk, Boehringer-Ingelheim Lilly, Astellas, Otsuka, Novartis and Baxter. CG-C has given scientific lectures and participated in advisory boards organized by Astra-Zeneca, Boehringer-Ingelheim Lilly, Mundipharma and NovoNordisk. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 García-Carro, Vergara, Bermejo, Azancot, Sellarés and Soler.)
- Published
- 2021
- Full Text
- View/download PDF
42. Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers.
- Author
-
Jacobs-Cachá C, Vergara A, García-Carro C, Agraz I, Toapanta-Gaibor N, Ariceta G, Moreso F, Serón D, López-Hellín J, and Soler MJ
- Abstract
Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30-50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS., (© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.)
- Published
- 2020
- Full Text
- View/download PDF
43. Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?
- Author
-
Draibe JB, García-Carro C, Martinez-Valenzuela L, Agraz I, Fulladosa X, Bolufer M, Tango A, Torras J, and Soler MJ
- Abstract
Background: The incidence of acute tubulointerstitial nephritis (ATIN) related to drugs has dramatically increased over recent years. A new subtype of ATIN, apparently different from classical drug-related ATIN, has emerged that has been related to the administration of immune checkpoint inhibitors (ICIs). We investigated these differences between ICI-related ATIN (ICI ATIN) and non-ICI-related ATIN in terms of clinical features, response to treatment with steroids and the evolution of kidney function., Methods: A total of 47 patients diagnosed with ATIN from two centres were recruited. Of these, 13 patients presented with ATIN during ICI treatment and 34 were diagnosed with ATIN attributed to other drugs. The main demographic, clinical and analytical variables such as gender, age and current medication were recorded. The type of malignancy, oncological treatment, ICI dose and presence of extrarenal immune-related adverse events were also reviewed. Renal biopsy diagnosis, time to drug withdrawal and ATIN-specific treatment, as well as laboratory data during follow-up, were also studied., Results: Patients diagnosed with ICI ATIN presented with lower creatinine (ICI ATIN 3.8 ± 1.03 versus classical ATIN 5.98 ± 4.15 mg/dL, P = 0.007) at diagnosis and higher urinary leucocyte counts (ICI ATIN 263.2 ± 418.04 versus classical ATIN 133.55 ± 284.62, P = 0.048) compared with patients with non-ICI-related ATIN. Time from initiation of the culprit drug to ATIN diagnosis was longer in patients with ICI ATIN than in those with classical ATIN (197.07 ± 184.99 versus 114.4 ± 352.16 days, P = 0.006). In addition, during follow-up, the slope of decreasing creatinine over time was lower for ICI ATIN compared with non-ICI-related ATIN., Conclusions: In this study, we analysed differences between ICI ATIN and classical ATIN. We found that patients with ICI ATIN presented with a larger latency period after culprit drug initiation, milder acute kidney injury and slower creatinine amelioration compared with those with classical ATIN. These results may, in part, be ascribed to potential differences in the pathological mechanisms involved in ATIN development, suggesting that ICI and classical ATIN may be different diseases with similar renal histologies., (© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.)
- Published
- 2020
- Full Text
- View/download PDF
44. Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience.
- Author
-
Oleas D, Bolufer M, Agraz I, Felip E, Muñoz E, Gabaldón A, Bury R, Espinel E, Serón D, García-Carro C, and Soler MJ
- Abstract
Background: Checkpoint inhibitors (CPIs) are used to treat solid organ metastatic malignancies. They act by triggering a vigorous immune response against tumoural cells, preventing their proliferation and metastasis. However, this is not a selective response and can cause immune-related adverse events (irAEs). The kidney can potentially be damaged, with an incidence of irAEs of 1-4%. The most frequent type of toxicity described is acute interstitial nephritis (AIN)., Methods: We conducted a study of patients with solid organ metastatic malignancies treated with immunotherapy who developed acute renal injury and underwent kidney biopsy in the last 14 months at the Vall d'Hebron University Hospital., Results: In all, 826 solid organ malignancies were treated with immunotherapy in our centre, 125 of them (15.1%) developed acute kidney injury (AKI), 23 (18.4% of AKI) visited the nephrology department and 8 underwent kidney biopsy. The most frequent malignancy was lung cancer, in five patients (62%), followed by two patients (25%) with melanoma and one patient (12%) with pancreatic cancer. Four patients (50%) had already received previous oncological therapy, and for the remaining four patients (50%), CPI was the first-line therapy. Five patients (62%) were treated with anti-programmed cell death protein 1, three patients (37%) received anti-programmed death ligand 1 and two (25%) patients were treated in combination with anti-cytotoxic T-lymphocyte antigen 4. The time between the start of CPI and the onset of the AKI ranged from 2 to 11 months. The most frequent urine findings were subnephrotic-range proteinuria, with a mean protein:creatinine ratio of 544 mg/g (standard deviation 147) and eosinophiluria. All patients were biopsied after being diagnosed with AIN. Three patients (37%) received treatment with pulses of methylprednisolone 250-500 mg/day and five patients (62%) received prednisone 1 mg/kg/day. Seven patients (87%) experienced recovery of kidney function and one patient (12%) progressed to chronic kidney disease., Conclusions: We report on eight patients with CPI-related AIN diagnosed in the last 14 months at our centre. The novel immunotherapy treatment of metastatic solid organ malignancies carries a higher risk of irAEs. The kidney is one of the most commonly affected organs, frequently presenting as an AIN and exhibiting a favourable response to steroid treatment., (© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.